Study reveals how diabetes drug metformin prevents, suppresses cancer growth

December 15, 2016
Metformin 500mg tablets. Credit: public domain

Considerable evidence has indicated that the drug metformin, used for more than 50 years to treat type 2 diabetes, also can prevent or slow the growth of certain cancers; but the mechanism behind its anticancer effects has been unknown. Now a team of Massachusetts General Hospital (MGH) investigators has identified a pathway that appears to underlie metformin's ability both to block the growth of human cancer cells and to extend the lifespan of the C.elegans roundworm, implying that this single genetic pathway plays an important role in a wide range of organisms.

"We found that metformin reduces the traffic of molecules into and out of the nucleus - the 'information center' of the cell," says Alexander Soukas, MD, PhD, of the MGH Center for Human Genetic Research, senior author of the study in the Dec. 15 issue of Cell. "Reduced nuclear traffic translates into the ability of the drug to block cancer growth and, remarkably, is also responsible for metformin's ability to extend lifespan. By shedding new light on metformin's health-promoting effects, these results offer new potential ways that we can think about treating cancer and increasing healthy aging."

Metformin's ability to lower blood glucose in patients with type 2 diabetes appears to result from the drug's effects on the liver—reducing the organ's ability to produce glucose for release into the bloodstream. Evidence has supported the belief that this is the result of metformin's ability to block the activity of mitochondria, structures that serve as the powerhouse of the cell. But while that explanation appears to be fairly straightforward, Soukas explains, more recent information suggests the mechanism is more complex.

Several studies have suggested that individuals taking metformin have a reduced risk of developing certain cancers and of dying from cancers that do develop. Current clinical trials are testing the impact of metformin on cancers of the breast, prostate and pancreas; and several research groups are working to identify its molecular targets. Soukas's team had observed that, just as it blocks the growth of cancer cells, metformin slows growth in C.elegans, suggesting that the roundworm could serve as a model for investigating the drug's effects on cancer.

Their experiments found that metformin's action against cancer relies on two elements of a single genetic pathway - the complex, which allows the passage of molecules into and out of the nucleus, and an enzyme called ACAD10. Basically, metformin's suppression of mitochondrial activity reduces cellular energy, restricting the traffic of molecules through the nuclear pore. This shuts off an important cellular growth molecule called mTORC1, resulting in activation of ACAD10, which both slows the growth and extends the lifespan of C.elegans.

In human melanoma and pancreatic cancer cells, the investigators confirmed that application of drugs in the metformin family induced ACAD10 expression, an effect that depended on the function of the . Without the complete signaling pathway - from mitochondrial suppression, through nuclear pore restriction to ACAD10 expression - cancer cells were no longer sensitive to the effects of metformin-like drugs.

"Amazingly, this pathway operates identically, whether in the worm or in human cancer cells," says Soukas, who is an assistant professor of Medicine at Harvard Medical School. "Our experiments showed two very important things: if we force the nuclear pore to remain open or if we permanently shut down ACAD10, metformin can no longer block the growth of . That suggests that the nuclear pore and ACAD10 may be manipulated in specific circumstances to prevent or even treat certain cancers."

The essential contribution of ACAD10 to 's anticancer action is intriguing, Soukas adds, because the only published study on ACAD10 function tied a variant in the gene to the increased risk of type 2 diabetes in Pima Indians, suggesting that ACAD10 also has a role in the drug's antidiabetes action. "What ACAD10 does is a great mystery that we are greatly interested in solving," he says. "Determining exactly how ACAD10 slows cell growth will provide additional insights into novel therapeutic targets for cancer and possibly ways to manipulate the pathway to promote healthy aging."

Explore further: Diabetes drug metformin corrects mitochondrial metabolism in familial cancer disorder

More information: Cell, DOI: 10.1016/j.cell.2016.11.055

Related Stories

Diabetes drug metformin corrects mitochondrial metabolism in familial cancer disorder

November 21, 2016
Individuals with Li-Fraumeni syndrome are at an increased risk for a number of cancers, including breast and bone cancer. Li-Fraumeni syndrome is an inherited cancer disorder caused by mutations in the tumor suppressing protein ...

Protein that protects during stress sheds light on how diabetes drug prevents tumors

November 21, 2016
Researchers at University of California San Diego School of Medicine have identified a previously unknown mechanism that helps fortify the structure and tight junctions between epithelial cells—a basic cell type that lines ...

Metformin may reduce cancer mortality risk

April 18, 2016
(HealthDay)—Metformin may reduce the risk of dying from some cancers for postmenopausal women with type 2 diabetes, according to a study published in the April 15 issue of the International Journal of Cancer.

Metformin confers anti-tumor immunity by reactivating exhausted CD8T lymphocytes

February 24, 2016
Anti-cancer effect of tumor infiltrating CD8+T lymphocyte (CD8TIL) is suppressed by interaction between immune-checkpoint molecules such as PD-1 and CTLA-4 expressed on CD8TIL and their ligands expressed on cancer cells, ...

Greater drop in hemoglobin A1c with empagliflozin plus metformin

August 16, 2016
(HealthDay)—Twenty-four weeks of empagliflozin + metformin correlates with a significantly greater reduction in hemoglobin A1c (HbA1c) compared with once-daily empagliflozin or twice-daily metformin, according to a study ...

Recommended for you

Researchers identify gene variants linked to a high-risk children's cancer

September 25, 2017
Pediatric researchers investigating the childhood cancer neuroblastoma have identified common gene variants that raise the risk of an aggressive form of that disease. The discovery may assist doctors in better diagnosing ...

MRI contrast agent locates and distinguishes aggressive from slow-growing breast cancer

September 25, 2017
A new magnetic resonance imaging (MRI) contrast agent being tested by researchers at Case Western Reserve University not only pinpoints breast cancers at early stages but differentiates between aggressive and slow-growing ...

Prostaglandin E1 inhibits leukemia stem cells

September 25, 2017
Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice.

Cancer vaccines need to target T cells that can persist in the long fight against cancer

September 25, 2017
Cancer vaccines may need to better target T cells that can hold up to the long fight against cancer, scientists report.

Lung cancer treatment could be having negative health effect on hearts

September 25, 2017
Radiotherapy treatment for lung cancer could have a negative effect on the health of your heart new research has found.

Alternative splicing, an important mechanism for cancer

September 22, 2017
Cancer, which is one of the leading causes of death worldwide, arises from the disruption of essential mechanisms of the normal cell life cycle, such as replication control, DNA repair and cell death. Thanks to the advances ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.